Pharmaceuticals

SunGen and Camber Announce U.S. Launch of Generic Version of Bentyl® (Dicyclomine) Injection

PRINCETON, New Jersey, Jan. 25, 2020 /PRNewswire/ -- SunGen Pharma, a privately held specialty pharmaceutical company which develops, contract manufactures, and sells pharmaceutical finished products, today announced the U.S. launch and commercial shipment of generic version of Bentyl® (Dicyclomi...

2020-01-25 06:16 469

CStone announces first patient dosed in the global proof-of-concept study of CS1001 in combination with Bayer's regorafenib

SUZHOU, China, Jan. 24, 2020 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) recently announced that it has dosed the first patient inAustralia in a clinical trial of CS1001, an investigational PD-L1 inhibitor developed by CStone, in combination with regorafenib, an...

2020-01-24 14:26 514

CStone successfully hosted the first U.S. R&D Day in New York

* Among CStone's 15 cancer drug candidates, five candidates are in pivotal late-stage clinical development, with a total of 13 on-going registrational trials. * The Company has implemented its pipeline strategy for early-stage candidates and combination therapy. With an established clinical d...

2020-01-24 08:18 509

CStone successfully hosted the first U.S. R&D Day in New York

* Among CStone's 15 cancer drug candidates, five candidates are in pivotal late-stage clinical development, with a total of 13 on-going registrational trials. * The Company has implemented its pipeline strategy for early-stage candidates and combination therapy. With an established clinical d...

2020-01-24 08:03 443

Inovio Selected by CEPI to Develop Vaccine Against New Coronavirus

PLYMOUTH MEETING, Pa., Jan. 24, 2020 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced the Coalition for Epidemic Preparedness Innovations (CEPI) has awarded Inovio a grant of up to$9 million to develop a vaccine against the recently emerged strain of coronavirus (2019-nCo...

2020-01-24 00:26 926

Eddy Cojulun New Chief Sales Officer at Envirotainer

UPPLANDS VASBY, Sweden, Jan. 22, 2020 /PRNewswire/ --  Envirotainer, the global market leader in secure cold chain solutions for air transport of pharmaceuticals, today announced thatEddy Cojulun joined Envirotainer as the new Chief Sales Officer (CSO) inDecember 2019. In his new role Eddy will r...

2020-01-22 15:27 315

US Food and Drug Administration (FDA) grants priority review of belantamab mafodotin for patients with relapsed or refractory multiple myeloma

* Biologics License Application based on results from the pivotal DREAMM-2 study of immunoconjugate targeting B-cell maturation antigen (BCMA) in heavily pre-treated patient population who was refractory to an immunomodulatory drug and a proteasome inhibitor, and refractory or intolerant to an ...

2020-01-21 22:00 4353

TenNor Therapeutics Received FDA Orphan Drug Designation

SUZHOU, China, Jan. 20, 2020 /PRNewswire/ -- TenNor Therapeutics, a clinical-stage, global biopharmaceutical company has received FDA Orphan Drug Designation for TNP-2092 to treat prosthetic joint infections. Medical devices such as prosthetic joints, central venous catheters and artificial hear...

2020-01-20 20:50 348

Bridge Biotherapeutics Announces FDA IND Clearance for BBT-176, an EGFR TKI for NSCLC

SEONGNAM, South Korea, Jan. 19, 2020 /PRNewswire/ -- Bridge Biotherapeutics Inc., a clinical stage biotech company headquartered in Seongnam, Republic of Korea, announced that the Investigational New Drug (IND) application submitted to the U.S. Food and Drug Administration (FDA) has been cleared ...

2020-01-20 10:44 283

QBiotics receives first registration for tigilanol tiglate with European Medicines Agency approval of Stelfonta(R)

* STELFONTA® (tigilanol tiglate) approved by the European Medicines Agency (EMA), making it the first pharmaceutical treatment available for all grades of canine non-metastatic mast cell tumours (MCT)[1] * The approval marks the first registration of QBiotic's, lead compound tigilanol tiglate...

2020-01-20 07:00 610

111, Inc. Featured at 38th Annual JP Morgan Healthcare Conference

SHANGHAI, Jan. 17, 2020 /PRNewswire/ -- Junling Liu, co-founder, Chairman, and Chief Executive Officer of 111, Inc. (NASDAQ: YI) a leading integrated online and offline healthcare platform, gave an address entitled "Driving Transformation inChina's Healthcare and Pharmaceutical Industry" at the 3...

2020-01-17 20:00 6535

China SXT Pharmaceuticals, Inc. Announced Regulatory Approval of Its DNA Exam Laboratory

TAIZHOU, China, Jan. 16, 2020 /PRNewswire/ -- China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces ("TCMPs"), including Ad...

2020-01-16 21:00 5133

WuXi Biologics and Bayer Enter into an Acquisition Agreement on a Drug Product Plant in Germany

* First drug product facility in Europe to complement WuXi Biologics' existing commercial manufacturing capacities * WuXi Biologics will be the back-up manufacturer for Kovaltry™ of Bayer SHANGHAI and LEVERKUSEN, Germany, Jan. 15, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a ...

2020-01-16 10:39 8580

FDF China to be held in June to boost Chinese pharmaceutical enterprises to "go global" and promote the innovation and development of industry

SHANGHAI, Jan. 16, 2020 /PRNewswire/ -- FDF China, collocated with CPhI China, will be held fromJune 22-24, 2020 at Shanghai New International Expo Centre (SNIEC). More and more formulation enterprises need to implement strategic layout to step up cooperation in innovation and facilitate the inte...

2020-01-16 09:52 448

Hanmi Pharmaceutical participated in the 38th J.P. Morgan Healthcare Conference, announces that it is "ready to lead global pharmaceutical market with innovative R&D pipeline"

SEOUL, South Korea, Jan. 15, 2020 /PRNewswire/ -- The company, led by President and CEO Se-chang Kwon and co-representative Jong-soo Woo, participated in the 38th J.P. Morgan Healthcare Conference inSan Francisco during Jan. 13-15, which it presented its vision and major R&D strategies for 2020. ...

2020-01-16 07:30 351

Genome & Company announces a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany and Pfizer

SEOUL, South Korea, Jan. 14, 2020 /PRNewswire/ -- Genome & Company (KONEX: 314130) is pleased to announce that it has entered into a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt,Germany and Pfizer Inc. to evaluate the safety, tolerability, biological and clinical ...

2020-01-14 08:00 499

COMPASS Pathways Granted Patent Covering Use of Its Psilocybin Formulation in Addressing Treatment-resistant Depression

LONDON, Jan. 13, 2020 /PRNewswire/ -- COMPASS Pathways, a mental health care company, announced today that it has been granted US Patent No 10,519,175, relating to methods of treating drug-resistant depression with a psilocybin formulation, by the US Patent and Trademark Office. The patent covers...

2020-01-13 19:05 328

Discover the Latest Information and Seize Market Opportunities in the Annual Event of the CRO & CMO Industry at ICSE China 2020

SHANGHAI, Jan. 13, 2020 /PRNewswire/ -- The ICSE China 2020 will take place in Hall E2, E3/E7 of Shanghai New International Expo Centre fromJune 22-24, 2020. It will gather Chinese and overseas pharmaceutical experts, showcase advanced products and technologies in the CRO & CMO area and explore f...

2020-01-13 17:34 378

Nanoform Appoints Head of US Sales

HELSINKI, Jan. 13, 2020 /PRNewswire/ -- Nanoform, an innovative nanoparticle medicine enabling company, has appointedSally Langa as Head of US Sales. The new role will enable Nanoform to continue its rapid growth with a strengthened presence in the US market. As Head of US Sales, Sally Langa wil...

2020-01-13 15:21 350

Tyvyt (Sintilimab Injection) Combined with ALIMTA (Pemetrexed) and Platinum Met Predefined Primary Endpoint in Phase 3 ORIENT-11 Study as First-Line Therapy in Nonsquamous NSCLC

SUZHOU, China, Jan. 13, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic and other major diseases, today jointly announced...

2020-01-13 12:42 7742
12345 ... 105